GoWit Secures Strategic Investment Led by Nuwa Capital to Drive the Next Era of AI Retail Media in EMEA
17.11.2025 09:09:00 CET | Business Wire | Press Release
GoWit, the leading AdTech company in connected commerce and retail media, announced a strategic investment round led by Nuwa Capital, with participation from existing investors Formus Capital, APY Ventures, and DCP.
The investment marks a milestone in GoWit’s mission to expand AI-powered commerce and retail media network and strengthen its leadership across EMEA.
Accelerating AI-Powered Retail Media Across EMEA
The new capital will fuel GoWit’s expansion and the development of next-generation AI tools to enhance ad performance, data intelligence, and monetization for retailers, brands, and agencies.
GoWit’s technology is trusted by leading retailers and marketplaces, including Carrefour (Turkey), Union Coop (UAE), Raneen (Egypt), Toters Delivery (Lebanon), Mumzworld (UAE), and Heureka Group (Czech Republic). The company collaborates with ecosystem partners such as Goldbach (Switzerland), Spike Media (MENA), and Akinon (EMEA), building a connected retail media infrastructure.
“We built the most intelligent, connected commerce and retail media network that enables every retailer, brand, and agency to grow profitably through a unified ad platform offering scalable technology, strong demand, and best-in-class operations,” said Emrah Adsan, Co-Founder and CEO of GoWit.
“Our success across MENA and Europe shows the strength of our technology and partnerships. This investment will accelerate our EMEA expansion and advance our AI-driven platform bringing next-level intelligence and automation to retail media.”
Rapid digital transformation across EMEA is creating one of the world’s most dynamic commerce markets. The MENA retail media market is projected to reach USD 6.35B by 2030, underscoring the potential for AI-driven advertising.
Powering Retail Media Through Unified Intelligence
GoWit enables full-funnel retail media activation, from on-site, off-site and in-store placements.
- For retailers: Launch and scale ad monetization quickly through an AI-powered platform, creating new revenue streams and maximizing performance.
- For brands: Access unified reporting, predictive automation, and AI optimization to drive smarter campaigns and stronger ROI.
- For agencies: Run retail media campaigns on a single platform, activate AI-powered targeting, and scale performance across retailers with full transparency.
Nuwa Capital Backing the Next-Generation of AdTech in MENA and Beyond
The round is led by Nuwa Capital, a Dubai-based venture firm investing across technology, commerce, and digital infrastructure. This investment marks Nuwa Capital’s first strategic move beyond MENA, underscoring GoWit’s global potential as a retail media technology powerhouse.
“Retail media is growing worldwide and accelerating in MENA. GoWit sets the bar in product, performance, and execution and delivers measurable ROI, clearly ahead of the field. We’ve been impressed by a team building to a truly global standard. We’re proud to lead this round as they scale across EMEA,” said Sarah Abu Risheh, Partner at Nuwa Capital.
About GoWit
GoWit is a leading AdTech company building EMEA’s largest Commerce and Retail Media Network, serving 7,000+ brands in 20+ markets. Its omnichannel AI-powered platform unifies technology, operations, and demand to help retailers, brands, and agencies maximize monetization and relevance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251117753802/en/
Contacts
GoWit
Begench Soyunov
+905416333166
begench@gowit.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom